The effect of D-cycloserine on brain processing of breathlessness over pulmonary rehabilitation - an experimental medicine study

Sarah L. Finnegan [1] (sarah.finnegan@ndcn.ox.ac.uk)

Olivia K. Harrison [1,2,3]

Sara Booth [10]

Andrea Dennis [12]

Martyn Ezra[1]

Catherine J. Harmer [4,5]

Mari Herigstad [6]

Bryan Guillaume [8]

Thomas E. Nichols [8,1]

Najib M. Rahman [7,9]

Andrea Reinecke [4]

Olivier Renaud [11]

Kyle T.S. Pattinson[1] (kyle.pattinson@nda.ox.ac.uk)

[1]. Wellcome Centre for Integrative Neuroimaging and Nuffield Division of Anaesthetics, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

[2]. Translational Neuromodeling Unit, Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Switzerland.

[3]. School of Pharmacy, University of Otago, Dunedin, New Zealand

[4]. Department of Psychiatry, Medical Sciences, University of Oxford, Oxford, UK;

[5]. Oxford Health NHS Foundation Trust, Warneford Hospital Oxford

[6]. Department of Biosciences and Chemistry, Sheffield Hallam University, Sheffield, UK

[7]. Nuffield Department of Medicine, University of Oxford, Oxford, UK

[8]. Oxford Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF UK

[9]. Oxford NIHR Biomedical Research Centre, Oxford OX3 7JX

[10]. Cambridge Breathlessness Intervention Service, Box 63, Elsworth House, CUNHSFT, Hills Road, Cambridge CB2 200

[11]. Department of Psychology, University of Geneva, Switzerland

[12]. Perspectum, Oxford, OX4 2LL

Corresponding author: Sarah L. Finnegan; sarah.finnegan@ndcn.ox.ac.uk

6th Floor, West Wing, John Radcliffe Hospital, Oxford, OX3 9DU; 01865 234 544

Author contributions

S.L.F – Acquisition of data, analysis, interpretation, drafting, editing and approving manuscript

O.K.H - Interpretation, editing and approving manuscript

S.B - Study design, editing and approving manuscript

A.D - Acquisition of data, analysis, approving manuscript

M.E – Analysis, editing and approving manuscript

B.G – Analysis, approving manuscript

C.J.H – Study design, editing and approving manuscript

M.H - Study design, acquisition of data, editing and approving manuscript

T.N – Analysis, approving manuscript

N.M.R - Study design, editing and approving manuscript

O.R – Analysis, approving manuscript

A.R - Study design, editing and approving manuscript

K.T.S.P - Study design, interpretation, editing and approving manuscript

Funding

This work was supported by the Dunhill Medical Trust (Grant R333/0214) and the National Institute for Health Research Biomedical Research Centre (Grant RCF18/002) based at Oxford University Hospitals NHS Foundation Trust and The University of Oxford. This research was funded in whole, or in part, by the Wellcome Trust 203139/Z/16/Z. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. OKH was supported via funding from the European Union's Horizon 2020 research and innovation programme under the Grant Agreement No 793580, and as a Rutherford Discovery Postdoctoral Fellow from the Royal Society of New Zealand. CJH is supported by the National Institute for Health Research Biomedical Research Centre based at Oxford Health NHS Foundation Trust and The University of Oxford, and by the UK Medical Research Council. KTSP and NMR are supported by the National Institute for Health Research Biomedical Research Centre based at Oxford University Hospitals NHS Foundation Trust and the University of Oxford. AR is funded by a fellowship from MQ. Transforming mental health.

Disclosures

Dr. Harmer has valueless shares in p1vital and serves on their advisory panel. She has received consultancy payments from p1vital, Zogenix, J&J, Pfizer, Servier, Eli-Lilly, Astra Zeneca, Lundbeck. Dr. Pattinson and Dr Ezra are named as co-inventors on a provisional U.K. patent application titled "Use of cerebral nitric oxide donors in the assessment of the extent of brain dysfunction following injury. Dr. Rahman, has received consulting fees from Rocket Medical U.K. Prof. Nichols has received consulting fees from Perspectum Diagnostics. The remaining authors have no biomedical financial interests or potential conflicts of interest.

Abstract

Background: Pulmonary rehabilitation is the best treatment for chronic breathlessness in COPD but there remains an unmet need to improve efficacy. Pulmonary rehabilitation has strong parallels with exposure-based cognitive behavioural therapies (CBT), both clinically and in terms of brain activity patterns. The partial NMDA-receptor agonist, D-cycloserine has shown promising results in enhancing efficacy of CBT, thus we hypothesised that it would similarly augment the effects of pulmonary rehabilitation in the brain. Positive findings would support further development in phase 3 clinical trials.

Methods: 72 participants with mild-to-moderate COPD were recruited to a double-blind pre-registered (ID: NCT01985750) experimental medicine study running parallel to a pulmonary rehabilitation course. Participants were randomised to 250mg D-cycloserine or placebo, administered immediately prior to the first four sessions of pulmonary rehabilitation. Primary outcome measures were differences between D-cycloserine and placebo in brain activity in the anterior insula, posterior insula, anterior cingulate cortices, amygdala and hippocampus following completion of pulmonary rehabilitation. Secondary outcomes included the same measures at an intermediate time point and voxel-wise difference across wider brain regions .

Results: No difference between D-cycloserine and placebo groups was observed across the primary or secondary outcome measures. Questionnaire and measures of respiratory function showed no group difference.

Conclusions: This is the first study testing brain-active drugs in pulmonary rehabilitation. Rigorous trial methodology and validated surrogate end-points maximised statistical power. Although increasing evidence supports therapeutic modulation of NMDA pathways to treat symptoms, we conclude that a phase 3 clinical trial of D-cycloserine would not be worthwhile.

Key Words: Neuroimaging, breathlessness-expectation, brain-active drugs, cognitive behavioural therapy

Introduction

Chronic breathlessness is a central symptom of chronic obstructive pulmonary disease (COPD). Currently, pulmonary rehabilitation offers the most effective treatment strategy for chronic breathlessness in COPD. However, around 30% of patients derive no clinical benefit [1]. Health-related benefits plateau within the first 6-months following pulmonary rehabilitation, returning to pre-rehabilitation levels for the majority of patients after 12-18 months [2, 3]. Thus, there remains an unmet need to develop strategies to increase or prolong the beneficial effects of pulmonary rehabilitation.

A body of evidence has shown that improvements in breathlessness over pulmonary rehabilitation result from a reappraisal of the sensory experience [4-7], arresting the downward spiral of fear, avoidance and physical deconditioning [6, 8]. The safe, graded exposure to breathlessness within pulmonary rehabilitation parallels techniques of exposure-based cognitive behavioural therapy (CBT), in which pathological fears are first activated and then disconfirmed by new adaptive information [9]. These similarities are highted by clinical studies of both pulmonary rehabilitation and cognitive behavioural therapy, which show changes to brain activity within areas associated with attention and learned sensory and emotional expectations such as cingulate cortex, angular gyrus, insula and supramarginal gyrus, [7, 10, 11].

In the field of psychiatry, there has been great interest in the partial NMDA agonist D-cycloserine, as a pharmacological adjunct to enhance efficacy of exposure-based CBT [12-15]. D-cycloserine is thought to act at the glycine modulatory site of the NMDA receptor. Its high affinity binding enhances synaptic plasticity, promoting emotional learning processes [14, 16] boosting therapeutic effects of CBT as a result [13, 17, 18]. Experimental medicine studies have demonstrated reductions in emotional response within the amygdala when paired with CBT [12, 19], increasing activity within hippocampus in a manner linked to learning [20]. In CBT for alcoholism, D-cycloserine

146 decreased cue induced brain activity across the ventral and dorsal striatum which was
147 associated with reductions in alcohol craving [21]. Clinical trials of D-cycloserine
148 paired with CBT have demonstrated reductions in symptoms of acrophobia [22], social
149 phobia [23], panic disorder [24] and obsessive compulsive disorder (OCD) [25] over
150 placebo [26-32], often with medium to large effect sizes.
151
152 Given the strong parallels between pulmonary rehabilitation and exposure-based CBT,
153 and the strong effects of pulmonary rehabilitation on affective components of
154 breathlessness [4, 7, 33] we hypothesised that D-cycloserine may have therapeutic
155 benefits in enhancing pulmonary rehabilitation.
156
157 To test this hypothesis, we performed an experimental medicine study using functional
158 magnetic resonance imaging (FMRI) markers of drug efficacy in the brain. We chose
159 this approach over a phase 3 clinical trial because the differences between COPD
160 populations and those with primary psychiatric conditions in which D-cycloserine has
161 been tested so far might necessitate a bespoke trial design. Therefore, we wanted to
162 test efficacy in the brain first. FMRI end-points are more sensitive than clinical ones
163 [34] and thus facilitate the adoption of more statistically robust approaches. This
164 means that results can be obtained with smaller sample sizes than in a phase 3 clinical
165 trial. A positive result from an FMRI study would facilitate clinical trial design and help
166 early decisions of go/no-go on further clinical development.
167

Methods and Materials

An overview of the methodology is presented here. Full details, including non-completion and sensitivity analysis can be found within supplementary materials. The study and statistical analysis plan were pre-registered on clinicaltrials.gov (ID: NCT01985750) prior to unblinding. This is the first example of pre-registration of both study design and analysis plan in a respiratory neuroimaging study.

Sample Size

At the time of study inception (and to a large extent still to date), the literature regarding D-cycloserine's effects on functional brain activity is very limited. Therefore, in order to calculate the sample sizes required for this study we first took into account the described effects of D-cycloserine in clinical studies of augmentation for cognitive behavioural therapy for anxiety disorders, where effect sizes of up to 1.06 have been reported (although more commonly 0.4 to 0.7) [22, 23, 35, 36]**.** The most relevant paper (on treatment of snake phobia [18]**)** demonstrated that effects observed with neuroimaging were more sensitive than behavioural effects, therefore powering for a behavioural outcome measure (breathlessness-anxiety) provided a safe margin and was likely to be sufficiently conservative to detect our measures of interest. This was particularly the case as compared to the relatively blunt nature of behavioural data collection, functional neuroimaging carries considerably more specificity and statistical power. The study was not therefore specifically powered to investigate the clinical effects of D-cycloserine. In our previous study we observed an 11% (SD15%) improvement in breathlessness-related anxiety, measured with our FMRI word task (pre-treatment mean score 38%, post treatment mean score 27%, difference 11%, SD of difference 15%) [7]. Making a conservative assumption, we estimated that D-cycloserine augments this response with an effect size of 0.4. Assuming a similar coefficient of variation we anticipated an 18% (SD24%) improvement in breathlessness-anxiety (i.e. pre-treatment mean score 38%, post treatment mean

196 score 20%, difference 18%, SD of difference 24%). Assuming α=0.05 and power 0.80,
197 then we estimated a sample size of 36 in each group randomised 1:1. As this is a
198 behavioural outcome, we expected this to have sufficient power to detect change in
199 BOLD signalling.
200
201 ***Participants***
202 91 participants (30 female, median age 70 years; range 46-85 years) with COPD were
203 recruited immediately prior to their enrolment in a National Health Service-prescribed
204 course of pulmonary rehabilitation (full demographic information including non-
205 continuation is shown in Supplementary material Table 1). From this population, 72
206 participants completed all study visits (18 female, median age 71 years (46-85 years))
207 (Table 1 and Figure 2). Written informed consent was obtained from all participants
208 prior to the start of the study. Study approval was granted by South Central Oxford
209 REC B (Ref: 118784, Ethics number: 12/SC/0713). Study inclusion criteria were: a
210 diagnosis of COPD and admittance to pulmonary rehabilitation. Exclusion criteria
211 were: inadequate understanding of verbal and written English, significant cardiac,
212 psychiatric (including depression under tertiary care) or metabolic disease (including
213 insulin-controlled diabetes), stroke, contraindications to either D-cycloserine (including
214 alcoholism) or magnetic resonance imaging (MRI), epilepsy, claustrophobia, regular
215 therapy with opioid analgesics or home oxygen therapy.
216
217 ***Study drug***
218 Participants were randomised in a double-blinded procedure to receive either 250mg
219 oral D-cycloserine or a matched placebo, administered by the study nurse 30 minutes
220 prior to the onset of their first four pulmonary rehabilitation sessions. 250mg dosage
221 has been shown to be efficacious [12, 20]. D-cycloserine exerts its best effects when
222 given immediately before exposure based therapy and only for a limited number of
223 times [37] with daily administration associated with tachyphylaxis [22]. Therefore, the

224 dose timing of D-cycloserine was deliberately selected to be the first four sessions,
225 where the greatest potential for emotional learning occurs as patients become
226 habituated to pulmonary rehabilitation. Study participants, investigators and those
227 performing the analysis were blinded to the treatment allocation. Both D-cycloserine
228 and placebo were over-encapsulated to appear identical.
229 The following minimization criteria were used for randomisation a) centre at which
230 pulmonary rehabilitation was performed, MRC breathlessness grade, presence of
231 diabetes, whether the participant was taking antidepressants, the age at which the
232 participant completed full time education and previous pulmonary rehabilitation. Full
233 details of randomisation can be found within the supplementary materials.
234
235 ***Study visit protocol***
236 Following telephone screening, participants were invited to attend their first research
237 session (baseline) prior to starting pulmonary rehabilitation. A second study visit took
238 place following the fourth pulmonary rehabilitation session but before the sixth session.
239 Participants completed the remainder of their pulmonary rehabilitation course before
240 attending a third study session (Figure 2) that occurred as close to the termination of
241 pulmonary rehabilitation as possible and always within two weeks.
242
243 ***Pulmonary Rehabilitation***
244 Pulmonary rehabilitation courses were run by either Oxford Health NHS Foundation
245 Trust, West Berkshire NHS Foundation Trust, or Milton Keynes University Hospitals
246 NHS Trust.
247
248 ***Self-report questionnaires*:**
249 Building on our previous work [7, 38] we selected a set of questionnaires with proven
250 sensitivity to changes across pulmonary rehabilitation [7], which were designed to
251 probe the experience of living with COPD. These were scored according to their

respective manuals: Dyspnoea-12 (D12) Questionnaire [39], Centre for Epidemiologic Studies Depression Scale (CES-D) [40], Trait Anxiety Inventory (TRAIT) [41], Fatigue Severity Scale [42], St George's Respiratory Questionnaire (SGRQ) [43], Medical Research Council (MRC) breathlessness scale [44], Mobility Inventory (MI) [45], Breathlessness catastrophising scale, adapted from the Catastrophic Thinking Scale in Asthma [46], Breathlessness vigilance, adapted from the Pain Awareness and Vigilance Scale [47].

Physiological measures:

Spirometry and two Modified Shuttle Walk Tests (MSWT) were collected using standard protocols [48, 49]. Participant height and weight were recorded at each visit. Oxygen saturations and heart rate were measured with pulse oximetry and were collected at rest and following the MSWT.

MRI measures

Image acquisition: Magnetic resonance imaging of the brain was carried out using a Siemens 3T MAGNETOM Trio. A T1-weighted (MPRAGE) structural scan (voxel size: 1 x 1 x 1 mm) was collected and used for registration purposes. A T2*-weighted, gradient echo planar image (EPI) scan sequence (voxel size: 3 x 3 x 3 mm), TR, 3000ms; TE 30ms was used to collect FMRI data.

Word cue task: To probe the neural responses of breathlessness-related expectations we examined the activity of brain regions responding to breathlessness-related word cues [7, 38, 50]. This paradigm has previously been shown to be sensitive to improvements in breathlessness over a course of pulmonary rehabilitation Brain activity was correlated with corresponding visual analogue ratings of breathlessness and breathlessness-anxiety collected during scanning. [7]. During FMRI scanning, participants were presented with a word cue, e.g., "climbing stairs" in white text on a

black background for 7 seconds. Participants were then asked, “how breathless would this make you feel” (wB) and “how anxious would this make you feel” (wA). To each question participants responded within a 7 second window using a button box and visual analogue scale (VAS). The response marker always initially appeared at the centre of the scale, with the anchors “Not at all” and “Very much” at either end.

Control task: A validated task of emotional faces was used as a control to separate generalized anxiety from breathlessness specific anxiety. Fearful or happy faces were presented on a black background was used to examine whether any differences in brain activity patterns between D-cycloserine and placebo groups was specific to breathlessness processing. Each face was shown for 500ms in blocks of 30 seconds. A fixation cross was interspersed for 30 seconds between the blocks of faces. Participants were instructed to respond via a button box to indicate facial gender. Reaction time and accuracy were recorded throughout the task.

Outcomes

Our primary outcomes focused on brain activity changes within five key regions of interest, identified in previous studies of breathlessness [7, 51-53]. The regions of the anterior insular cortex, posterior insular cortex, anterior cingulate cortex, amygdala and hippocampus have all been linked to body and symptom perception as well as emotional salience [51, 54]. Focusing on a small number of regions of interest is more statistically powerful and therefore more likely to detect a hypothesised difference. Secondary hypotheses examined the effect of D-cycloserine across a wider region of interest containing fifteen pre-defined brain areas. The fifteen brain areas encompassed regions associated with sensory and affective processing of breathlessness as well as body and symptom perception. regions.

Analysis

A summary of analyses is outlined here. Full details, including procedures for dealing with missing data and sensitivity analysis can be found within the supplementary materials. Our analysis was pre-registered and made publicly available prior to unblinding https://mfr.osf.io/render?url=https://osf.io/wqyf4/?action=download%26mode=render.

Brain imaging analysis

Image processing was carried out using the Oxford Centre for Functional Magnetic Resonance Imaging of Brain Software Library (FMRIB, Oxford, UK; FSL version 5.0.8; https://ww.fmrib.ox.ac.uk/fsl/), MATLAB R2018b (Mathworks, Natick, MA), R-studio, R version 3.6.1 (2019-07-05). and associated custom scripts. Functional MRI processing was performed using FEAT (FMRI Expert Analysis Tool, within the FSL package).

Data were pre-processed according to standard protocols before being entered into single subject general linear models. These models captured brain activity during the periods in which the breathlessness-related word cues were presented allowing us to examine expectation-related processes.

Group level analysis

For each patient, the following metrics were extracted from each of the five regions of interest: anterior insula cortex, posterior insula cortex, anterior cingulate cortex, amygdala and hippocampus, at visits one, two and three:

1. Mean brain activity in response to breathlessness word-cue presentation
2. Mean brain activity for control task of emotional faces

To test for a drug effect across each metric, the values from visit two were entered into independent linear mixed effects models where they were adjusted for age, gender

and scores at visit one. To correct for multiple comparisons across regions, permutation testing (with Family Wise Error Rate (FWE) 5%) was carried out. This process was repeated separately for data collected at visit three. Models were programmed using the lme4 function and permuco package within R version 3.6.1 (2019-07-05).

To test for a drug effect across the larger region of interest (panel B of Supplementary Figure 1), the following voxel-wise information was collected from within the region of interest at visits one, two and three:

1. Voxel-wise brain activity in response to breathlessness word-cues presentation
2. Voxel-wise brain activity in response the control task of emotional faces

Each of the values from visit two were entered into independent general linear model (GLM), controlling for age, gender and scores at visit one. Permutation testing was performed with threshold free cluster enhancement (TFCE) (a non-parametric test) [55] using FSL's Randomise tool [56] at family wise error corrected $p<0.05$. The process was then repeated separately for data collected at visit three.

Results

Of the 91 participants recruited (Figure 1), 72 participants completed all three study visits. Reasons for drop-out or exclusion included illness, scanner error and issues with data quality. One further participant was excluded due to an error in task-data collection. 71 participants were therefore assessed for study objectives. Sensitivity analysis was performed and is reported within supplementary materials.

Primary outcomes

There was no significant overall effect of D-cycloserine on mean brain activity within the five key regions of interest of anterior cingulate, anterior insula cortex, amygdala, hippocampus or posterior insula cortex (family wise error rate corrected, $p>0.05$) at visit two or visit three (Table 2 and Table 3).

Secondary outcomes

There was no significant overall effect of D-cycloserine across the broader mask of fifteen regions measured voxel-wise (family wise error rate correct, $p>0.05$) at visit two or visit three.

No significant differences in the questionnaire measures or physiology scores were found between the D-cycloserine and placebo groups at any point during the study. No differences were observed between the two groups either in breathlessness ratings (wB) or breathlessness related anxiety (wA) at visit two (both $p=0.15$ family wise error rate corrected) (Table 4) or visit three (both $p=0.053$ family wise error rate corrected) (Table 5). No significant effect of drug group was identified, using repeat measured ANOVA's, for the emotional faces control task (collected during FMRI scanning) at visit two ($F(1,68) = 0.17$, $p=0.68$) or visit three ($F(1,68) = 0.001$, $p=0.97$). Furthermore, no significant interaction between drug group and emotional valence (happy or fearful

384 faces) was identified at visit two ($F(1,68) = 0.36$, $p=0.55$) (Table 4) or visit three ($F(1,68)$

385 $= 0.002$, $p=0.97$) (Table 5). Raw scores are reported in Supplementary Table 4.

386

387 Overall changes in self-report questionnaires over the course of pulmonary

388 rehabilitation were as expected and are presented in Supplementary Table 5.

389
390
391
392

393 **Discussion**

394

395 ***Key Findings***

396 We found that 250mg of D-cycloserine administered prior to the first four sessions of
397 pulmonary rehabilitation showed no effect on breathlessness related brain activity in
398 the 5 regions of interest tested: amygdala, anterior insula, posterior insula, anterior
399 cingulate cortex or hippocampus when assessed either during (after 4-5 sessions) or
400 after the course. Neither was there any effect on the secondary endpoints of voxel-
401 wise activity across a wider selection of brain regions. These findings suggest that D-
402 cycloserine does not have the potential to move to phase 3 clinical trials in pulmonary
403 rehabilitation and that alternative drug candidates should be considered.

404

405 This is the first study to test a neuro-pharmacological adjunct to pulmonary
406 rehabilitation. A key strength of this study, in addition to its sample size, which is large
407 for a neuroimaging study of breathlessness, is its use of robust clinical trial
408 methodology which was monitored in accordance with GCP standards. We included a
409 formal sample size calculation powered for validated end points relevant to the patient
410 population, pre-registered the study design and published a statistical analysis plan
411 ahead of unblinding. Additionally, our hypotheses focused on five a-priori defined brain
412 regions with demonstrated evidence of strong modulation by D-cycloserine [17, 57] or
413 links to body, symptom perception as well as emotional salience [51, 54]. Together
414 these steps, which are rarely carried out for neuroimaging studies, ensured rigorous
415 methodology, robust findings and provide the best chance to detect an effect if present.

416

Why was no drug effect observed?

D-cycloserine may be too "weak". While D-cycloserine has not shown sufficient promise to be progressed to full-scale clinical trials, other drugs may now be more attractive candidates. As a stand-alone treatment for treatment resistant depression, ketamine, which blocks pre-synaptic NMDA receptor signalling, increasing glutamate and thereby synaptic plasticity, has been linked with reductions in fear and anxiety [58], and rapid relief from symptoms [59].

Individual differences: Recent literature has highlighted the importance of individual differences in response to D-cycloserine. New evidence suggests that D-cycloserine has the potential to reinforce either positive or negative experiences during exposure based CBT [28], which may render brain activity differences unobservable in a simple contrast of means.

Ceiling effect: The action of D-cycloserine is known to be curtailed near the therapeutic ceiling [60], and pulmonary rehabilitation is a highly effective treatment [2], this may leave insufficient scope for improvement in some individuals. This is a highly likely explanation for the lack of observed drug effect. Other studies may consider pairings of less effective treatments with neuro-pharmacological adjuncts.

Little evidence of D-cycloserine in older adults: Mechanisms of drug effect may occur via mediated activity within hippocampus, amygdala and insula, regions which overlap with brain networks of internal bodily sensation (interoception) and reappraisal [12, 17, 18]. Given that our previous work, which examined changes in brain activity over a course of pulmonary rehabilitation, identified decreased brain activity within insula correlating with improvements to breathlessness [7], we hypothesised D-

445 cycloserine would work on this body and reappraisal network. However, older adults
446 are not well represented within the evidence base regarding D-cycloserine's action.
447 Given the well-established changes to NMDA receptor function as the brain ages, D-
448 cycloserine may act differently in this population [61].
449
450 **Alternative brain pathways may be more relevant.** While glucocorticoids such as
451 cortisol, combined with exposure-based CBT, have shown promise in reduction of fear
452 in phobias and post-traumatic stress disorder [13] via their action on the hypothalamic-
453 pituitary-adrenal (HPA) axis. Selective serotonin uptake inhibitors (SSRIs) are another
454 potential drug class of interest. Paired with CBT, Paroxetine reduced panic attacks by
455 50% compared to placebo [62]. While further evidence suggests that the combination
456 of drug and CBT is more effective than either CBT or Paroxetine alone, highlighting
457 the potential value of combination therapies [63]. However the downside of paroxetine
458 is.....x, y and z.....
459 Collectively these candidate drugs boost synaptic plasticity, although via different
460 neurochemical pathways, which may facilitate the re-setting of fearful associations
461 within the brain. These could be used either during pulmonary rehabilitation, or as part
462 of a precursor programme, helping to recruit harder to reach patients and support self-
463 management. Successful self-management has been highlighted as a key objective
464 by the department of health [64] and often follows on from CBT-based programmes
465 such as the talking therapies recommended by the British Lung Foundation
466
467 **Dosing and dose timing.** Questions do still remain regarding D-cycloserine's
468 optimum dosage, dose timing and number of administered sessions [26, 65]. One
469 recent literature review suggests that up to nine doses, delivered 60-minutes before
470 exposure may yield the best results and increase effect size by up to 50% [26]. Based
471 on the available literature at the time [12, 14] and practical considerations regarding
472 drug availability, we selected a dose of 250mg for this study, administered at the first

four rehabilitation sessions. However, given that our maximum effect size was 0.18 (Figure 3), even a 50% increase would be below the commonly reported effect sizes of 0.4-0.7, and up to 1.06 [18, 22, 23, 36]. This strongly suggests that dose and dose timing did not drive the negative result.

Conclusions

We have shown evidence that D-cycloserine does not have an effect on breathlessness related brain activity, behavioural or physiological measures over the course of pulmonary rehabilitation. This study contributes important information regarding the (un)suitability of D-cycloserine as a candidate for phase 3 clinical trials in pulmonary rehabilitaiton.

Acknowledgements

The authors would like to thank Jane Francis and the radiography team at the Oxford Centre for Magnetic Resonance Imaging; Beverly Langford, Eleanor Evans and Anja Hayen for their assistance with data collection; Oxford, Reading and Milton Keynes pulmonary rehabilitation teams with particular thanks to Emma Tucker and Chris Swindale, Katy Beckford and Catherine Darby, Milan Bhattacharya and Louise Worrall and the Oxford Respiratory Trials Unit.

References

1. Garrod, R., et al., *Predictors of success and failure in pulmonary rehabilitation.* European Respiratory Journal, 2006. **27**(4): p. 788.
2. Haave, E. and M. Hyland, *Different short-term and longitudinal results on perceived health status for asthma and COPD patients after pulmonary rehabilitation. Patients living alone have the largest improvements in perceived quality of life.* Chron Respir Dis, 2008. **5**(2): p. 69-73.
3. Walsh, J.R., et al., *Longevity of pulmonary rehabilitation benefit for chronic obstructive pulmonary disease—health care utilisation in the subsequent 2 years.* BMJ Open Respiratory Research, 2019. **6**(1): p. e000500.
4. Carrieri-Kohlman, V., et al., *Additional evidence for the affective dimension of dyspnea in patients with COPD.* Research in Nursing & Health, 2010. **33**(1): p. 4-19.
5. Janssens, T., et al., *Dyspnea Perception in COPD: Association Between Anxiety, Dyspnea-Related Fear, and Dyspnea in a Pulmonary Rehabilitation Program.* Chest, 2011. **140**(3): p. 618-625.
6. Reijnders, T., et al., *The impact of disease-specific fears on outcome measures of pulmonary rehabilitation in patients with COPD.* Respiratory Medicine, 2019. **146**: p. 87-95.
7. Herigstad, M., et al., *Treating breathlessness via the brain: changes in brain activity over a course of pulmonary rehabilitation.* Eur Respir J, 2017. **50**(3).
8. Corhay, J.-L., et al., *Pulmonary rehabilitation and COPD: providing patients a good environment for optimizing therapy.* International journal of chronic obstructive pulmonary disease, 2014. **9**: p. 27-39.
9. Kaczkurkin, A.N. and E.B. Foa, *Cognitive-behavioral therapy for anxiety disorders: an update on the empirical evidence.* Dialogues in clinical neuroscience, 2015. **17**(3): p. 337-346.
10. Reinecke, A., et al., *Early effects of exposure-based cognitive behaviour therapy on the neural correlates of anxiety.* Translational psychiatry, 2018. **8**(1): p. 225-225.
11. Reinecke, A., et al., *Effective emotion regulation strategies improve fMRI and ECG markers of psychopathology in panic disorder: implications for psychological treatment action.* Translational Psychiatry, 2015. **5**(11): p. e673-e673.
12. Reinecke, A., et al., *Neurocognitive processes in d-cycloserine augmented single-session exposure therapy for anxiety: A randomized placebo-controlled trial.* Behaviour Research and Therapy, 2020. **129**: p. 103607.
13. Singewald, N., et al., *Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.* Pharmacol Ther, 2015. **149**: p. 150-90.
14. Woud, M.L., et al., *Investigating d-cycloserine as a potential pharmacological enhancer of an emotional bias learning procedure.* J Psychopharmacol, 2018. **32**(5): p. 569-577.
15. Hofmann, S.G., et al., *D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder.* Am J Psychiatry, 2013. **170**(7): p. 751-8.

16. Davis, M., et al., *Effects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work.* Biological Psychiatry, 2006. **60**(4): p. 369-375.
17. Klass, A., et al., *d-Cycloserine facilitates extinction learning and enhances extinction-related brain activation.* Neurobiol Learn Mem, 2017. **144**: p. 235-247.
18. Nave, A.M., D.F. Tolin, and M.C. Stevens, *Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study.* J Clin Psychiatry, 2012. **73**(9): p. 1179-86.
19. Ebrahimi, C., et al., *Combining D-cycloserine with appetitive extinction learning modulates amygdala activity during recall.* Neurobiol Learn Mem, 2017. **142**(Pt B): p. 209-217.
20. Onur, O.A., et al., *The N-Methyl-D-Aspartate Receptor Co-agonist D-Cycloserine Facilitates Declarative Learning and Hippocampal Activity in Humans.* Biological Psychiatry, 2010. **67**(12): p. 1205-1211.
21. Kiefer, F., et al., *Effects of d-cycloserine on extinction of mesolimbic cue reactivity in alcoholism: a randomized placebo-controlled trial.* Psychopharmacology, 2015. **232**(13): p. 2353-2362.
22. Ressler, K.J., et al., *Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.* Arch Gen Psychiatry, 2004. **61**(11): p. 1136-44.
23. Hofmann, S.G., et al., *Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.* Arch Gen Psychiatry, 2006. **63**(3): p. 298-304.
24. Otto, M.W., et al., *Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder.* Biol Psychiatry, 2010. **67**(4): p. 365-70.
25. Kushner, M.G., et al., *D-Cycloserine Augmented Exposure Therapy for Obsessive-Compulsive Disorder.* Biological Psychiatry, 2007. **62**(8): p. 835-838.
26. Rosenfield, D., et al., *Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis.* J Anxiety Disord, 2019. **68**: p. 102149.
27. Hofmann, S.G., et al., *Cognitive enhancers for anxiety disorders.* Pharmacol Biochem Behav, 2011. **99**(2): p. 275-84.
28. Hofmann, S.G., *D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse.* Depress Anxiety, 2014. **31**(3): p. 175-7.
29. Otto, M.W., et al., *Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.* Biological Psychiatry, 2016. **80**(4): p. 274-283.
30. Hofmann, S.G., et al., *Is it Beneficial to Add Pharmacotherapy to Cognitive-Behavioral Therapy when Treating Anxiety Disorders? A Meta-Analytic Review.* International journal of cognitive therapy, 2009. **2**(2): p. 160-175.
31. Hofmann, S.G., *Schrödinger's Cat and d-Cycloserine to Augment Exposure Therapy—Both Are Alive and DeadSchrödinger's Cat and D-Cycloserine to Augment Exposure TherapyEditorial.* JAMA Psychiatry, 2016. **73**(8): p. 771-772.

32. Mataix-Cols, D., et al., *D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.* JAMA Psychiatry, 2017. **74**(5): p. 501-510.
33. Carrieri-Kohlman, V., et al., *Dyspnea and the affective response during exercise training in obstructive pulmonary disease.* Nurs Res, 2001. **50**(3): p. 136-46.
34. Burggren, A. and J. Brown, *Imaging markers of structural and functional brain changes that precede cognitive symptoms in risk for Alzheimer's disease.* Brain imaging and behavior, 2014. **8**(2): p. 251-261.
35. Rodebaugh, T.L., C.A. Levinson, and E.J. Lenze, *A high-throughput clinical assay for testing drug facilitation of exposure therapy.* Depression and anxiety, 2013. **30**(7): p. 631-637.
36. Guastella, A.J., et al., *A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder.* Biol Psychiatry, 2008. **63**(6): p. 544-9.
37. Norberg, M.M., J.H. Krystal, and D.F. Tolin, *A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy.* Biol Psychiatry, 2008. **63**(12): p. 1118-26.
38. Herigstad, M., et al., *Dyspnea-related cues engage the prefrontal cortex: evidence from functional brain imaging in COPD.* Chest, 2015. **148**(4): p. 953-961.
39. Yorke, J., et al., *Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12.* 2010. **65**(1): p. 21-26.
40. Radloff, L.S., *The CES-D Scale:A Self-Report Depression Scale for Research in the General Population.* 1977. **1**(3): p. 385-401.
41. Spielberger, C.D., *State-Trait Anxiety Inventory*, in *The Corsini Encyclopedia of Psychology*. 2010.
42. Krupp, L.B., et al., *The fatigue severity scale: Application to patients with multiple sclerosis and systemic lupus erythematosus.* Archives of Neurology, 1989. **46**(10): p. 1121-1123.
43. Jones, P.W., et al., *A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.* Am Rev Respir Dis, 1992. **145**(6): p. 1321-7.
44. Bestall, J.C., et al., *Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.* Thorax, 1999. **54**(7): p. 581-586.
45. Chambless, D.L., et al., *The Mobility Inventory for Agoraphobia.* Behav Res Ther, 1985. **23**(1): p. 35-44.
46. De Peuter, S., et al., *Illness-specific catastrophic thinking and overperception in asthma.* Health Psychol, 2008. **27**(1): p. 93-9.
47. McCracken, L.M., K.E. Vowles, and C. Eccleston, *Acceptance-based treatment for persons with complex, long standing chronic pain: a preliminary analysis of treatment outcome in comparison to a waiting phase.* Behav Res Ther, 2005. **43**(10): p. 1335-46.
48. Bradley, J., et al., *Validity of a modified shuttle test in adult cystic fibrosis.* Thorax, 1999. **54**(5): p. 437-9.
49. Levy, M.L., et al., *Diagnostic spirometry in primary care: Proposed standards for general practice compliant with American Thoracic Society*

640 *and European Respiratory Society recommendations: a General Practice*
641 *Airways Group (GPIAG)1 document, in association with the Association for*
642 *Respiratory Technology & Physiology (ARTP)2 and Education for Health3 1*
643 *www.gpiag.org 2 www.artp.org 3 www.educationforhealth.org.uk.* Prim
644 Care Respir J, 2009. **18**(3): p. 130-47.
645 50. Herigstad, M., et al., *Development of a dyspnoea word cue set for studies of*
646 *emotional processing in COPD.* Respiratory physiology & neurobiology,
647 2016. **223**: p. 37-42.
648 51. Faull, O.K., A. Hayen, and K.T.S. Pattinson, *Breathlessness and the body:*
649 *Neuroimaging clues for the inferential leap.* Cortex; a journal devoted to
650 the study of the nervous system and behavior, 2017. **95**: p. 211-221.
651 52. Banzett, R.B., et al., *Breathlessness in humans activates insular cortex.*
652 Neuroreport, 2000. **11**(10): p. 2117-20.
653 53. Esser, R.W., et al., *Brain Activation during Perception and Anticipation of*
654 *Dyspnea in Chronic Obstructive Pulmonary Disease.* Frontiers in
655 physiology, 2017. **8**: p. 617-617.
656 54. Craig, A.D., *How do you feel--now? The anterior insula and human*
657 *awareness.* Nat Rev Neurosci, 2009. **10**(1): p. 59-70.
658 55. Nichols, T.E. and A.P. Holmes, *Nonparametric permutation tests for*
659 *functional neuroimaging: A primer with examples.* Human Brain Mapping,
660 2002. **15**(1): p. 1-25.
661 56. Winkler, A.M., et al., *Permutation inference for the general linear model.*
662 Neuroimage, 2014. **92**: p. 381-97.
663 57. Thompson, L.T., J.R. Moskal, and J.F. Disterhoft, *Hippocampus-dependent*
664 *learning facilitated by a monoclonal antibody or D-cycloserine.* Nature,
665 1992. **359**(6396): p. 638-641.
666 58. Glue, P., et al., *Effects of ketamine in patients with treatment-refractory*
667 *generalized anxiety and social anxiety disorders: Exploratory double-blind*
668 *psychoactive-controlled replication study.* J Psychopharmacol, 2020. **34**(3):
669 p. 267-272.
670 59. Berman, R.M., et al., *Antidepressant effects of ketamine in depressed*
671 *patients.* Biol Psychiatry, 2000. **47**(4): p. 351-4.
672 60. Choi, D.C., et al., *Pharmacological Enhancement of Behavioral Therapy:*
673 *Focus on Posttraumatic Stress Disorder*, in *Behavioral Neurobiology of*
674 *Anxiety and Its Treatment*, M.B. Stein and T. Steckler, Editors. 2010,
675 Springer Berlin Heidelberg: Berlin, Heidelberg. p. 279-299.
676 61. Kumar, A. and T.C. Foster, *Alteration in NMDA Receptor Mediated*
677 *Glutamatergic Neurotransmission in the Hippocampus During Senescence.*
678 Neurochemical Research, 2019. **44**(1): p. 38-48.
679 62. Oehrberg, S., et al., *Paroxetine in the Treatment of Panic Disorder a*
680 *Randomised, Double-Blind, Placebo-Controlled Study.* British Journal of
681 Psychiatry, 1995. **167**(3): p. 374-379.
682 63. Nordahl, H.M., et al., *Paroxetine, Cognitive Therapy or Their Combination in*
683 *the Treatment of Social Anxiety Disorder with and without Avoidant*
684 *Personality Disorder: A Randomized Clinical Trial.* Psychotherapy and
685 Psychosomatics, 2016. **85**(6): p. 346-356.
686 64. Health, D.o., *An Outcomes Strategy for Chronic Obstructive Pulmonary*
687 *Disease (COPD) and Asthma.* 2011.

688 65. Hofmann, S.G., et al., *Dose timing of D-cycloserine to augment cognitive*
689 *behavioral therapy for social anxiety: Study design and rationale.*
690 Contemporary clinical trials, 2015. **43**: p. 223-230.
691

692

693 **FIGURES LEGENDS**

694

695 ***Figure 1.*** *Consort diagram illustrating stages of participant recruitment from initial screening*

696 *through to completion at visit 3.*



697

698

699

700

701

702

703

704

705

706

707

708

709

710 ***Figure 2.*** *A schematic demonstrating order of visits, rehabilitation sessions and tablet*
711 *administration throughout the study period. Participants took part in one study visit prior to their*
712 *first pulmonary rehabilitation session. Study drug/placebo were administered on four occasions*
713 *over the first four rehabilitation sessions. A second study visit occurred after the final*
714 *drug/placebo administration. Participants continued with their pulmonary rehabilitation course*
715 *for a further four weeks before returning for a third study visit.*



716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744

745 ***Figure 3.*** *Effect sizes and confidence intervals for each of the five regions of interest at visits*

746 *two and three for D-cycloserine and Placebo groups.*

747



748

749 **TABLES**

750

751 ***Table 1.*** *Demographic information from the 72 participants who completed all three study visits.*
752 *Variance is expression either in terms of standard deviation (SD) or interquartile range (IQR)*
753 *depending on the normality of the underlying data distribution.* ***BMI*** *= Body Mass Index,* ***MRC***
754 *= Medical Research Council.* ***SpO_2%*** *= Peripheral Oxygen saturation, expressed as a*
755 *percentage.* ***FEV*** *= Forced Expiratory Volume.* ***FVC*** *= Forced Vital Capacity. Also listed with*
756 *prevalence in brackets are recorded comorbidities ordered by frequency*

	Visit 1 (Pre-rehabilitation)	
	D-cycloserine	**Placebo**
Age (median years / range)	**71.0 / (47-81)**	**71.5 / (46-85)**
Smoking pack-years (years / IQR)	**34.0 / (25.6)**	**30.0 / (30.0)**
Duration of breathlessness (years / IQR)	**8.0 (17.0)**	**9.5 (10.0)**
Total exacerbations (number / IQR)	**0.0 (1.0)**	**1.0 (2.3)**
BMI (kg.m-2 ± SD)	**27.3 ± 6.5**	**26.9 ± 5.7**
MRC breathlessness scale (IQR)	**3.0 (1)**	**2.5 (1)**
Resting SpO_2% (IQR)	**95 / (3.3)**	**95 / (3.0)**
Resting heart rate (beats.min-1 ± SD)	**80.8 ± 13.4**	**80.8 ± 14.9**
FEV1/FVC (IQR)	**0.53 / (0.17)**	**0.56 / (0.13)**
	Comorbidities (frequency)	
	Asthma (14)	Asthma (11)
	Hypertension (13)	Hypertension (11)
	Gastro-oesophageal reflux (10)	Gastro-oesophageal reflux (12)
	Swelling of both ankles (11)	Swelling of both ankles (8)
	Surgery to the chest (6)	Surgery to the chest (7)
	Depression (6)	Depression (2)
	Diabetes (3)	Diabetes (6)
	Heart attack (4)	Heart attack (5)
	Bronchiectasis (3)	Bronchiectasis (4)
	Osteoporosis (2)	Osteoporosis (4)
	Arrhythmia (3)	Arrhythmia (4)
	Inflammatory bowel disease (2)	Inflammatory bowel disease (3)
	Peptic ulcer (3)	Peptic ulcer (2)
	Heart failure (1)	Heart failure (1)
	Tuberculosis (1)	Neuromuscular weakness (2)

757

758 ***Table 2.*** *Significance of overall effect of D-cycloserine on mean brain activity within the five key*
759 *regions of interest at visits two, having accounted for scores at visit one. Significance is reported*
760 *as Family Wise Error (p<0.05) corrected p-values of the difference*

Region of interest	*Estimate*	*Std. Error*	*Visit two (p-value)*
Anterior cingulate cortex	*0.066*	*0.059*	*0.70*
Anterior insula	*0.019*	*0.058*	*0.98*
Amygdala	*0.097*	*0.059*	*0.40*
Hippocampus	*0.018*	*0.058*	*0.98*
Posterior insula	*-0.013*	*0.059*	*0.98*

761

762

763 ***Table 3.*** *Significance of overall effect of D-cycloserine on mean brain activity within the five key*
764 *regions of interest at visits three, having accounted for scores at visit one. Significance is*
765 *reported as Family Wise Error (p<0.05) corrected p-values of the difference*

Region of interest	*Estimate*	*Std. Error*	*Visit three (p-value)*
Anterior cingulate cortex	*-0.009*	*0.056*	*0.98*
Anterior insula	*0.019*	*0.055*	*0.98*
Amygdala	*0.055*	*0.056*	*0.78*
Hippocampus	*0.014*	*0.056*	*0.98*
Posterior insula	*0.068*	*0.056*	*0.70*

766

767

768

769

770

771

772

773

774
775
776 ***Table 4.*** *Scores on questionnaire, behavioural and physiological measures for drug and*
777 *placebo group during (visit two). Measures are expressed as a "change score". Values are*
778 *calculated as baseline visit (visit one) minus the later visit, thus positive values indicate an*
779 *improvement or, in the case of the faces task, a faster reaction time (ms). Significance is*
780 *reported as Family Wise Error (p<0.05) corrected p-values of the difference in scores between*
781 *drug and placebo groups at visit two, accounting for scores at visit one. Values are either*
782 *recorded as mean and standard deviation (1) or as median and interquartile range (2)*
783 *depending on the normality of distribution.* ***BMI*** *= Body Mass Index,* ***MRC*** *= Medical Research*
784 *Council clinical measure of breathlessness,* ***MSWT =*** *Modified Shuttle Walk Test,* ***HR*** *= Heart*
785 *rate,* ***Sats*** *= Peripheral Oxygen saturation, expressed as a percentage*

	Visit Two		
	D-cycloserine	**Placebo**	**p-value**
Catastrophising	**1.0 (5.3) [2]**	**2.0 (4.0) [2]**	**0.84**
Depression	**1.2 ± 6.4 [1]**	**3.2 ± 5.4 [1]**	**0.55**
D12	**3.8 ± 5.4 [1]**	**2.2 ± 4.7 [1]**	**0.55**
Fatigue	**7.0 (12.3) [2]**	**4.5 (12.0) [2]**	**0.64**
BMI	**-0.16 (0.6) [2]**	**0.0 (0.6) [2]**	**0.55**
MRC	**0 (0.5) [2]**	**0 (0.0) [2]**	**0.85**
MSWT Distance (m)	**0.0 (111.3) [2]**	**5.0 (70) [2]**	**0.85**
MSWT Borg Start	**0 (1) [2]**	**0 (1) [2]**	**0.85**
MSWT Borg Change	**0.5 (1.5) [2]**	**0.5 (2) [2]**	**0.85**
MSWT HR Start	**-0.30 ± 13.9 [1]**	**1.4 ± 13.2 [1]**	**0.85**
MSWT HR Change	**-45.4 ± 23.0 [1]**	**-47.5 ± 25.4 [1]**	**0.90**
MSWT Sats Start	**-0.30 ± 2.2 [1]**	**-0.1 ± 2.2 [1]**	**0.85**
MSWT Sats Change	**0 (5) [2]**	**0 (4.0) [2]**	**0.91**
Vigilance	**3.8 ± 10.6 [1]**	**1.8 ± 13.6 [1]**	**0.85**
FEV1/FVC	**0 (0.1) [2]**	**0 (0.1) [2]**	**0.55**
Avoidance – Alone	**0.1 (0.4) [2]**	**0.1 (0.2) [2]**	**0.91**
Avoidance -Accompanied	**0.0 (0.3) [2]**	**0.1 (0.2) [2]**	**0.55**
St George – Active	**6.7 (10.6) [2]**	**3.3 (12.8) [2]**	**0.55**
St George – Impact	**4.3 ± 7.7 [1]**	**1.5 ± 8.1 [1]**	**0.55**
St George – Symptom	**4.0 ± 11.5 [1]**	**4.3 ± 10.7 [1]**	**0.92**
Trait	**4.0 (5.5) [2]**	**1.0 (7.0) [2]**	**0.55**
Breathlessness Anxiety (wA)	**0.4 (29.0) [2]**	**5.0 (17.8) [2]**	**0.15**
Breathlessness Severity (wB)	**-0.4 ± 21.3 [1]**	**9.2 ± 23.1 [1]**	**0.15**
Fearful Faces (ms)	**5.2 (116.5)**	**-13.5 (73.0)**	
Happy Faces (ms)	**12.1 (112.8)**	**-1.9 (106.9)**	
Main effect of drug group	**F(1,68) = 0.17, p=0.68**		
Interaction drug group:emotion	**F(1,68) = 0.36, p=0.55**		

786
787
788
789
790

Table 5. *Scores on questionnaire, behavioural and physiological measures for drug and placebo group following pulmonary rehabilitation (visit three). Measures are expressed as a "change score". Values are calculated as baseline visit (visit one) minus the later visit, thus positive values indicate an improvement or, in the case of the faces task, a faster reaction time (ms). Significance is reported as Family Wise Error (p<0.05) corrected p-values of the difference in scores between drug and placebo groups at visit three, accounting for scores at visit one. Values are either recorded as mean and standard deviation (1) or as median and interquartile range (2) depending on the normality of distribution.* ***BMI*** *= Body Mass Index,* ***MRC*** *= Medical Research Council clinical measure of breathlessness,* ***MSWT =*** *Modified Shuttle Walk Test,* ***HR*** *= Heart rate,* ***Sats*** *= Peripheral Oxygen saturation, expressed as a percentage.*

	Visit Three		
	D-cycloserine	**Placebo**	**p-value**
Catastrophising	**3.0 (7) [2]**	**4.5 (8) [2]**	**0.86**
Depression	**3.1 ± 6.6 [1]**	**4.7 ± 5.3 [1]**	**0.86**
D12	**3.0 (8.3) [2]**	**2.5 (8) [2]**	**0.86**
Fatigue	**9.7 ± 12.5 [1]**	**5.7 ± 12.0 [1]**	**0.86**
BMI	**0.0 (0.8) [2]**	**-0.1 (0.9) [2]**	**0.86**
MRC	**0 (1) [2]**	**0 (1) [2]**	**0.86**
MSWT Distance (m)	**40 (92.5) [2]**	**30 (70) [2]**	**0.86**
MSWT Borg Start	**0 (0.5) [2]**	**0 (1) [2]**	**0.86**
MSWT Borg Change	**0.1 ± 1.9 [1]**	**-0.1 ± 1.6 [1]**	**0.86**
MSWT HR Start	**2.7 ± 10.4 [1]**	**2.4 ± 13.5 [1]**	**0.98**
MSWT HR Change	**-51 (29.3) [2]**	**-53.5 (27) [2]**	**0.86**
MSWT Sats Start	**0.0 (2) [2]**	**0.0 (3) [2]**	**0.86**
MSWT Sats Change	**-1 (7) [2]**	**0 (3) [2]**	**0.86**
Vigilance	**5.0 (12) [2]**	**5.5 (12) [2]**	**0.86**
Spirometry	**0 (0.1) [2]**	**0 (0.1) [2]**	**0.86**
Avoidance – Alone	**0.1 (0.3) [2]**	**0.1 (0.3) [2]**	**0.98**
Avoidance -Accompanied	**0.0 (0.3) [2]**	**0.1 (0.3) [2]**	**0.86**
St George – Active	**6.0 (15.1) [2]**	**6.2 (13.4) [2]**	**0.86**
St George – Impact	**5.1 (12.7) [2]**	**5.0 (8.6) [2]**	**0.86**
St George – Symptom	**6.5 ± 12.5 [1]**	**6.4 ± 12.7 [1]**	**0.97**
Trait	**2.7 ± 5.8 [1]**	**3.3 ± 7.6 [1]**	**0.86**
Breathlessness Anxiety (wA)	**3.0 (7.0) [2]**	**7.3 (16.8) [2]**	**0.053**
Breathlessness Severity (wB)	**3.1 (15.6) [2]**	**8.4 (13.1) [2]**	**0.053**
Fearful Faces (ms)	**-0.2 (70.7)**	**-58.2 (88.4)**	
Happy Faces (ms)	**-10.5 (126.7)**	**-43.5 (106.4)**	
Main effect of drug group	**F(1,68) = 0.001, p=0.97**		
Interaction drug group:emotion	**F(1,68) = 0.002, p=0.97**		